Esmojet-SR Capsule is a combination pharmaceutical formulation containing Domperidone 30 mg and Esomeprazole 40 mg, designed for the management of gastrointestinal disorders associated with acid reflux and delayed gastric emptying. Domperidone, a peripheral dopamine D2 receptor antagonist, facilitates gastric motility and accelerates gastric emptying, thereby alleviating symptoms such as nausea, vomiting, and bloating. Esomeprazole, a proton pump inhibitor (PPI), effectively suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system in gastric parietal cells, providing symptomatic relief from gastroesophageal reflux disease (GERD), erosive esophagitis, and peptic ulcers. The sustained-release formulation ensures prolonged therapeutic plasma concentrations, enhancing efficacy and patient compliance by reducing dosing frequency. Esmojet-SR is indicated for patients requiring combined prokinetic and acid-suppressive therapy, particularly in cases where monotherapy is insufficient. It should be administered under medical supervision, with caution advised in patients with underlying cardiac conditions or those on medications that may interact with Domperidone or Esomeprazole. Common adverse effects may include headache, dry mouth, and gastrointestinal disturbances. Contraindications include hypersensitivity to either component and concurrent use with QT-prolonging agents. Proper diagnosis and adherence to prescribed dosage are essential for optimal therapeutic outcomes.